You have 9 free searches left this month | for more free features.

Revlimid

Showing 26 - 50 of 598

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Lymphoma Trial in Houston (Rituximab, Lenalidomide, Valemetostat)

Not yet recruiting
  • Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jan 4, 2023

CNS Lymphoma, Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in San Francisco (Tafasitamab, Lenalidomide)

Recruiting
  • CNS Lymphoma
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Aug 10, 2022

Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHL Trial in Houston (Mosunetuzumab, Polatuzumab vedotin, Tafasitamab)

Not yet recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 7, 2022

Diffuse Large B Cell Lymphoma Trial (Epcoritamab, Lenalidomide)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • (no location specified)
Jan 20, 2023

Multiple Myeloma Trial in United States (KRdD followed by auto-HCT, KRdD only)

Active, not recruiting
  • Multiple Myeloma
  • KRdD followed by auto-HCT
  • KRdD only
  • Birmingham, Alabama
  • +3 more
Mar 26, 2022

Alkylating Agent-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia Trial in Houston (Laboratory Biomarker

Completed
  • Alkylating Agent-Related Acute Myeloid Leukemia
  • Secondary Acute Myeloid Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Oct 18, 2022

Chronic Lymphocytic Leukemia Trial in Cologne (lenalidomide, Placebo)

Completed
  • Chronic Lymphocytic Leukemia
  • Cologne, Germany
  • +1 more
Dec 16, 2021

Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma Trial in Wuhan (Daratumumab, Carfilzomib,

Recruiting
  • Multiple Myeloma
  • +2 more
  • Wuhan, Hubei, China
    Institute of Hematology, Union Hospital, Tongji Medical College,
Nov 18, 2023

Leukemia, Lymphoma Trial in Houston (Rituximab, Lenalidomide)

Active, not recruiting
  • Leukemia
  • Lymphoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Oct 11, 2022

CNS Tumors Trial in Saint Petersburg (25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 50 mg/m2

Terminated
  • Central Nervous System Tumors
  • 25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
  • +4 more
  • Saint Petersburg, Florida
    Johns Hopkins All Childen's Hospital
Mar 8, 2021

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Tampa (High Dose Methylprednisolone (HDMP), Ofatumumab,

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • High Dose Methylprednisolone (HDMP)
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jan 12, 2023

Multiple Myeloma Trial in Rochester (Daratumumab, Lenalidomide, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Rochester, New York
    University of Rochester Medical Center
Jul 8, 2022

Multiple Myeloma Trial in Atlanta (Bortezomib, Lenalidomide, Dexamethasone)

Completed
  • Multiple Myeloma
  • Atlanta, Georgia
    Emory University Winship Cancer Institute
Nov 1, 2021

Multiple Myeloma Trial in New York (Clarithromycin, Lenalidomide, Dexamethasone)

Completed
  • Multiple Myeloma
  • Clarithromycin, Lenalidomide, Dexamethasone
  • New York, New York
    Weill Medical College of Cornell University
May 26, 2021

Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma (MZL)
  • Chiang Mai, Thailand
    Chiang Mai University
Nov 20, 2023

Multiple Myeloma Trial in Boston, Columbus (drug, biological, other)

Terminated
  • Multiple Myeloma
  • Boston, Massachusetts
  • +1 more
Nov 14, 2022

Plasma Cell Myeloma Trial in Buffalo (Belantamab Mafodotin, Lenalidomide)

Recruiting
  • Plasma Cell Myeloma
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 5, 2022

Relapsed/Refractory Marginal Zone Lymphoma Trial in Westbury (Zanubrutinib, Rituximab, Lenalidomide)

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Westbury, New York
    Clinical Research Alliance, Inc.
Nov 14, 2022

Multiple Myeloma Trial in Chicago, Evanston, Ann Arbor (Elotuzumab, Carfilzomib, Lenalidomide)

Active, not recruiting
  • Multiple Myeloma
  • Chicago, Illinois
  • +2 more
Nov 12, 2021

Plasma Cell Myeloma, Transplant-Related Carcinoma Trial in Seattle (Ixazomib Citrate, Laboratory Biomarker Analysis,

Active, not recruiting
  • Plasma Cell Myeloma
  • Transplant-Related Carcinoma
  • Ixazomib Citrate
  • +2 more
  • Seattle, Washington
    Fred Hutchinson Cancer Research Center
Jul 12, 2022

Multiple Myeloma Trial in Shanghai (Selinexor, Thalidomide, Lenalidomide)

Recruiting
  • Multiple Myeloma
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Mar 3, 2022

Smoldering Multiple Myeloma Trial in Boston (Ixazomib, Lenalidomide, Dexamethasone)

Active, not recruiting
  • Smoldering Multiple Myeloma
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 15, 2022

Lenalidomide / Dexamethasone as First Line Therapy in Multiple

Active, not recruiting
  • Multiple Myeloma
    • Bochum, Germany
      Hämatologisch-Onkologische Schwerpunktpraxis
    Feb 1, 2022

    High-risk Smoldering Multiple Myeloma, Multiple Myeloma Trial in Boston (Daratumumab, Bortezomib, Lenalidomide)

    Recruiting
    • High-risk Smoldering Multiple Myeloma
    • Multiple Myeloma
    • Boston, Massachusetts
    • +1 more
    Oct 18, 2021

    Multiple Myeloma Trial in Little Rock (Carfilzomib, Thalidomide, Dexamethasone)

    Active, not recruiting
    • Multiple Myeloma
    • Little Rock, Arkansas
      University of Arkansas for Medical Sciences
    Sep 1, 2022